Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. has announced a release of voting rights as informed by the Netherlands Authority for the Financial Markets (AFM), highlighting BlackRock, Inc.’s significant holdings in the company. The notification reveals BlackRock’s substantial indirect capital interest and voting rights in Qiagen, which could impact the company’s governance and decision-making processes.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,401,871
Technical Sentiment Signal: Buy
Current Market Cap: $10.46B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.